MNG1050
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.548
- MYC_TARGETS_V2+0.247
- P53_PATHWAY+0.146
- KRAS_SIGNALING_DN+0.115
- PEROXISOME+0.110
- BILE_ACID_METABOLISM+0.107
- FATTY_ACID_METABOLISM+0.100
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.099
- ADIPOGENESIS+0.075
- CHOLESTEROL_HOMEOSTASIS+0.068
Top 10 suppressed
- G2M_CHECKPOINT-0.517
- MITOTIC_SPINDLE-0.503
- INTERFERON_GAMMA_RESPONSE-0.495
- E2F_TARGETS-0.483
- INTERFERON_ALPHA_RESPONSE-0.470
- ALLOGRAFT_REJECTION-0.408
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.383
- IL6_JAK_STAT3_SIGNALING-0.368
- PROTEIN_SECRETION-0.344
- TGF_BETA_SIGNALING-0.337
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LL-A6FP-01A-11R-A31O-07 | — | B | 0.879 |
| 2 | TCGA-AC-A3YJ-01A-11R-A22U-07 | — | B | 0.863 |
| 3 | TCGA-A7-A3RF-01A-11R-A22K-07 | — | B | 0.861 |
| 4 | TCGA-GM-A2DC-01A-11R-A18M-07 | — | B | 0.857 |
| 5 | MNG341 | — | — | 0.853 |
| 6 | SRR23303740 | — | — | 0.843 |
| 7 | TCGA-CF-A47W-01A-11R-A23W-07 | — | — | 0.841 |
| 8 | SRR4296114 | — | cohortA1 | 0.835 |
| 9 | TCGA-OR-A5L3-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.830 |
| 10 | TCGA-UF-A7JF-01A-11R-A34R-07 | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.548 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.247 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.146 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.115 | Remibrutinib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.107 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.099 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.075 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.068 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.054 | Cobimetinib | — uncovered |
| HYPOXIA | 0.032 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.007 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.001 | Inavolisib | — uncovered |